In conclusion, we identified HLA antibodies in patients and number of CD19 + and/or CD3 + cells in the graft to be associated with the development of moderate to severe cGVHD in patients with AML or MDS who received a NMA AlloPBSCT. This evidence concerns the gene CD19 and myelodysplastic syndrome.